statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran (BNT122, RO7198457) continue to show polyspecific T cell...

Three-year Phase 1 Follow-Up Data  for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer

DekaBank Deutsche Girozentrale boosted its stake in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 43.1% during the fourth quarter, according to the company in its most recent filing with the...

DekaBank Deutsche Girozentrale Buys 127,951 Shares of BioNTech SE (NASDAQ:BNTX)

Fifth Third Bancorp boosted its position in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 3,881.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC...

BioNTech SE (NASDAQ:BNTX) Shares Bought by Fifth Third Bancorp

BioNTech SE (NASDAQ:BNTX  Get Free Report) has been assigned a consensus rating of Hold from the ten ratings firms that are covering the stock, MarketBeat.com reports. One...

BioNTech SE (NASDAQ:BNTX) Given Consensus Rating of "Hold" by Brokerages

WuXi Biologics Reports Solid 2023 Annual Results WuXi Biologics Reports Solid 2023 Annual Results PR Newswire HONG KONG, March 26, 2024 Revenue Increased by 11.6% Y-o-Y to RMB17,034.3 Million Gross...

WuXi Biologics Reports Solid 2023 Annual Results

Shares of BioNTech SE (NASDAQ:BNTX  Get Free Report) have earned an average rating of Hold from the twelve ratings firms that are currently covering the company, Marketbeat...

Brokerages Set BioNTech SE (NASDAQ:BNTX) PT at $142.43

Q4 2023 BioNTech SE Earnings Call Transcript

This indicator may be signaling that BNTX's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

BioNTech SE American Depositary Share (BNTX, $90.02) entered Downtrend as Momentum indicator drops below 0 level on Mar 20, 2024

Advanced oncology pipeline in mid- and late-stage with plans to have ten or more potentially registrational oncology trials running by the end of 2024Aiming for first oncology launch in 2026 and ten...

BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

Mainz, Germany, March 20, 2024 (GLOBE NEWSWIRE) BioNTech SE (Nasdaq: BNTX, BioNTech or the Company ) announced today that the Supervisory Board has appointed Annemarie Hanekamp to the Management...

BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Watchers	19,009
52-Wk Low	$85.21
52-Wk High	$125.83

Volume	343,979.00
52-Wk High	$125.83
52-Wk Low	$85.21

BNTX BioNTech SE - ADR

About

Feed

News

Sentiment

Earnings

Fundamentals